Safety concerns for immunoglobulin preparations have led us to study partition/inactivation of two prototype retroviruses, mouse xenotropic type C and lymphadenopathy-associated virus (LAV) of the acquired immunodeficiency syndrome (AIDS), during manufacture and storage of immunoglobulins. Reduction of infectious retrovirus titers were 10(5) to 10(8)-fold through Cohn-Oncley cold ethanol fractionation from plasma to fraction II, 10(3) to 10(5)-fold through incubation at pH 4.0 and another 10(4)-fold through incubation of the purified liquid immunoglobulin preparations at 27 degrees C or 45 degrees C. The results support the clinical and epidemiological evidence that therapeutic immunoglobulin preparations do not transmit AIDS virus.
No takes yet. Share an insight, caveat, or question.
Mitra et al. (1986) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: